• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.

作者信息

Launchbury A P, Habboubi N

机构信息

Farmitalia Carlo Erba Ltd, St Albans, UK.

出版信息

Cancer Treat Rev. 1993 Jul;19(3):197-228. doi: 10.1016/0305-7372(93)90036-q.

DOI:10.1016/0305-7372(93)90036-q
PMID:8334677
Abstract
摘要

相似文献

1
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
Cancer Treat Rev. 1993 Jul;19(3):197-228. doi: 10.1016/0305-7372(93)90036-q.
2
Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.表柔比星与多柔比星的心脏毒性：成本与临床结果。
J Clin Oncol. 2005 Apr 20;23(12):2873; author reply 2873-4. doi: 10.1200/JCO.2005.05.332.
3
Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.表柔比星与多柔比星膀胱内灌注治疗浅表性膀胱癌预防性疗效的比较：一项多中心随机试验。神户大学泌尿外科肿瘤学组
Cancer Chemother Pharmacol. 1994;35 Suppl:S46-51. doi: 10.1007/BF00686919.
4
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.在接受多柔比星或表柔比星化疗治疗癌症的患者中使用右丙亚胺作为心脏保护剂。省级系统治疗疾病部位组。
Cancer Prev Control. 1999 Apr;3(2):145-59.
5
Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
Cancer Chemother Pharmacol. 1994;35 Suppl:S97-100. doi: 10.1007/BF00686930.
6
A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.4'-表阿霉素用于复发性浅表性膀胱癌预防性膀胱内化疗的II期研究：4'-表阿霉素与阿霉素的比较
Cancer Chemother Pharmacol. 1994;35 Suppl:S52-6. doi: 10.1007/BF00686920.
7
Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study.
Eur J Haematol. 1991 May;46(5):301-5. doi: 10.1111/j.1600-0609.1991.tb01543.x.
8
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.多柔比星与表柔比星治疗转移性乳腺癌患者的对比研究。
Am J Clin Oncol. 1989 Feb;12(1):57-62. doi: 10.1097/00000421-198902000-00014.
9
[Comparison of the cytotoxic activity of doxorubicin and epirubicin by an in vitro test].[通过体外试验比较阿霉素和表阿霉素的细胞毒性活性]
Pol Arch Med Wewn. 1989 Aug-Sep;82(2-3):71-6.
10
[Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma].[在CHOP方案中给予恶性非霍奇金淋巴瘤患者阿霉素和表柔比星的疗效比较]
Wiad Lek. 1993 May;46(9-10):356-9.

引用本文的文献

1
Sigma-1 receptor activation attenuates DOX-induced cardiotoxicity by alleviating endoplasmic reticulum stress and mitochondrial calcium overload via PERK and IP3R-VDAC1-MCU signaling pathways.西格玛-1受体激活通过PERK和IP3R-VDAC1-MCU信号通路减轻内质网应激和线粒体钙超载，从而减轻阿霉素诱导的心脏毒性。
Biol Direct. 2025 Feb 25;20(1):23. doi: 10.1186/s13062-025-00617-y.
2
Different DNA Binding and Damage Mode between Anticancer Antibiotics Trioxacarcin A and LL-D49194α1.抗癌抗生素三恶唑菌素A和LL-D49194α1之间不同的DNA结合与损伤模式
JACS Au. 2024 Sep 10;4(9):3641-3648. doi: 10.1021/jacsau.4c00611. eCollection 2024 Sep 23.
3
Epimerisation in Peptide Synthesis.
肽合成中的差向异构化。
Molecules. 2023 Dec 8;28(24):8017. doi: 10.3390/molecules28248017.
4
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.安罗替尼作为一线化疗后晚期软组织肉瘤的维持治疗（ALTER-S006）：一项多中心、开放标签、单臂、2期试验。
EClinicalMedicine. 2023 Sep 21;64:102240. doi: 10.1016/j.eclinm.2023.102240. eCollection 2023 Oct.
5
Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.儿科肿瘤学中使用的抗癌药物的等效剂量：文献综述及一种新型转化因子评估方法。
Cancer Rep (Hoboken). 2023 May;6(5):e1811. doi: 10.1002/cnr2.1811. Epub 2023 Mar 28.
6
Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.载阿霉素和氧氟沙星的磁荧光介孔纳米载体的双重递药用于解决结直肠癌中的机会性细菌感染
Int J Mol Sci. 2022 Oct 14;23(20):12287. doi: 10.3390/ijms232012287.
7
Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational study.接受含或不含利妥昔单抗的CHOP方案治疗的恶性淋巴瘤患者蒽环类药物诱导的心脏毒性的临床特征：一项单中心回顾性观察研究
EJHaem. 2020 Oct 3;1(2):498-506. doi: 10.1002/jha2.110. eCollection 2020 Nov.
8
The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial.表柔比星与环磷酰胺对比多西他赛与环磷酰胺治疗淋巴结阴性、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的安全性比较（ELEGANT）：一项随机试验
Cancers (Basel). 2022 Jun 30;14(13):3221. doi: 10.3390/cancers14133221.
9
Ventricular Sigmoid Septum as a Risk Factor for Anthracycline-Induced Cancer Therapeutics-Related Cardiac Dysfunction in Patients With Malignant Lymphoma.室性乙状结肠间隔作为恶性淋巴瘤患者蒽环类药物诱导的癌症治疗相关心脏功能障碍的危险因素。
Circ Rep. 2022 Mar 26;4(4):173-182. doi: 10.1253/circrep.CR-21-0145. eCollection 2022 Apr 8.
10
Synthetic (,-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs.合成（−二甲基）多柔比星糖苷非对映异构体解析蒽环类抗癌药物的作用模式。
J Org Chem. 2021 Apr 16;86(8):5757-5770. doi: 10.1021/acs.joc.1c00220. Epub 2021 Mar 30.